Additionally, Ghosh et al. (40) demonstrated that allogeneic donor CD19-specific CD28z CAR T cells could promote anti-lymphoma activity by non-alloreactive cells, which retained activity against CD19+ targets, with minimal GVHD by exhaustion and eventual deletion of the alloreactive CAR-T cells. The gene discussed is CD19; the disease is lymphoma.